Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions.
about
Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infectionAdverse effects of antiretroviral therapy for HIV infectionThe Serostatus Approach to Fighting the HIV Epidemic: prevention strategies for infected individualsA binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivoCauses of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapyA complex systems approach to evaluate HIV prevention in metropolitan areas: preliminary implications for combination intervention strategiesA very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAARTA Population-Level Evaluation of the Effect of Antiretroviral Therapy on Cancer Incidence in Kyadondo County, Uganda, 1999-2008Which method of adherence measurement is most suitable for daily use to predict virological failure among immigrant and non-immigrant HIV-1 infected patients?Adherence to antiretroviral therapy in Nigeria: an overview of research studies and implications for policy and practice.Systematic identification of synergistic drug pairs targeting HIVA Comparison of Methods for Analyzing Viral Load Data in Studies of HIV Patients.The Role of Caveolin 1 in HIV Infection and Pathogenesis.Host sequence motifs shared by HIV predict response to antiretroviral therapyThe capsid protein of human immunodeficiency virus: designing inhibitors of capsid assembly.Combinatorial therapy discovery using mixed integer linear programming.Barriers to Hepatitis C Virus (HCV) Treatment Initiation in Patients With Human Immunodeficiency Virus/HCV Coinfection: Lessons From the Interferon Era.Temporal trends in treatment outcomes for HIV-1 and HIV-2-infected adults enrolled in Côte d'Ivoire's national antiretroviral therapy program.African American race and HIV virological suppression: beyond disparities in clinic attendance.Conspiracy beliefs about HIV are related to antiretroviral treatment nonadherence among african american men with HIV.Comparative efficacy versus effectiveness of initial antiretroviral therapy in clinical trials versus routine carePhenotypic hypersusceptibility to multiple protease inhibitors and low replicative capacity in patients who are chronically infected with human immunodeficiency virus type 1.Age and racial/ethnic differences in the prevalence of reported symptoms in human immunodeficiency virus-infected persons on antiretroviral therapy.Mobile Text Messaging to Improve Medication Adherence and Viral Load in a Vulnerable Canadian Population Living With Human Immunodeficiency Virus: A Repeated Measures StudyPredictors of success with highly active antiretroviral therapy in an antiretroviral-naive urban population.Gender disparities in HIV health care utilization among the severely disadvantaged: can we determine the reasons?Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North AmericaFour-year treatment outcomes of adult patients enrolled in Mozambique's rapidly expanding antiretroviral therapy program.Women and HIV--revisited ten years on.Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters.Recovery and analysis of human immunodeficiency virus type 1 (HIV) RNA sequences from plasma samples with low HIV RNA levels.Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adultsGenotypic susceptibility scores and HIV type 1 RNA responses in treatment-experienced subjects with HIV type 1 infection.Short-term discontinuation of HAART regimens more common in vulnerable patient populations.Healthcare Economics in HIV.Effectiveness of highly active antiretroviral therapy (HAART) among HIV-infected patients in MexicoManagement of HIV infection in patients with substance use problemsAdverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria.Resistance evolution in HIV - modeling when to intervene.
P2860
Q24536249-852EA9E6-B51D-4313-902B-EB3629F91FE4Q24617882-766853BD-532F-4F7D-AE35-9F5E31FAD7A8Q28205170-86F1236E-5757-476D-A404-918DB3BB16F3Q28344177-8D2DDABE-9E9E-48CB-98A9-AC0C975A3E31Q28362194-9378437D-00D1-4BC9-BEA6-9159B0A384E0Q28389988-0C9E24FB-A376-4D4A-8989-EBA8F4A5357DQ28483747-AC19C9F5-95DA-409A-B878-D86C77A10EBFQ28542548-53B6A109-410D-4DE7-8B00-4CAF62F91953Q28647861-7982101C-BD6F-455A-A48E-CE87CF48D5CFQ29353869-97499FAD-4A99-43E6-83B8-5AFAF3076A7AQ30409638-0432DF9E-9A46-42C9-A26C-5552AD607D4DQ30422333-BAE54DD2-6E8B-4828-8830-1E79F5A9A691Q30975343-74329FD5-74FC-41FC-9563-EA40210D082CQ32183747-F8CBF98E-FCC8-4AA0-890D-E6D9469750F1Q33486144-3841F131-A790-46E8-916E-DB0E51B8E64CQ33510254-E864FC0F-A447-4A3D-BCCB-B49E0E3B4231Q33593388-29585727-1E5E-4A04-A3BD-E2D59F36839BQ33629538-61810DD6-C904-4A3E-AEAA-8853DCC301B1Q33670735-04818F88-1CBF-43C9-B914-969EA4A67F8FQ33735032-75508802-AB4F-4D3D-B2B4-3E23451B5EBCQ33753905-6959F91A-0EC7-4964-9AAE-5345E439B25CQ33766361-46B8747C-2A07-434D-8E50-B2C30986507FQ33780566-FAE745CF-FC30-4B94-B19F-B47AA4F9A751Q33803909-2256392A-613A-4BC3-8C03-8157DF45C6BEQ33804916-72572AF5-B74A-4FAC-9E82-2DD1C0D803A9Q33807518-9B270426-D5EC-40E9-85BB-69D0F215FF57Q33810823-70AC9978-1533-4B1F-A0F4-5092AF0144C0Q33853922-822E6555-3E4F-4FC3-AE8F-1C0137A0A9D5Q33869315-72B94F2A-840F-4D07-B0AF-1144F63DE924Q33926171-512D35EA-B926-4B23-ADEF-8E686AB193E1Q33952995-03BCDD55-6082-4CCF-BBE6-4CD4F6C05B87Q33974840-27A7B6DA-3936-41D9-9A36-FE56AF7E5AA5Q33980711-FB0B7B32-2DF1-4D4C-A415-04D123E301ACQ34084316-4896F696-EB7E-4A0D-8A69-67587707F497Q34085103-AE19A983-61B1-45B1-9F58-599B0259D7A2Q34092289-4EAB0C14-B1C1-495E-982B-CE8293B5B9C1Q34103178-F3813F4F-E72A-478E-A47A-0B44B94156B4Q34113784-D1009BB0-A83A-4CEC-9BAA-8BEE400E0B90Q34174009-4F2F0DD5-FE73-4282-A3BA-E18038FC0ECDQ34247013-7ECE4FCB-9BA5-42F0-B806-82C60D74A643
P2860
Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Highly active antiretroviral t ...... re and adverse drug reactions.
@en
Highly active antiretroviral t ...... re and adverse drug reactions.
@nl
type
label
Highly active antiretroviral t ...... re and adverse drug reactions.
@en
Highly active antiretroviral t ...... re and adverse drug reactions.
@nl
prefLabel
Highly active antiretroviral t ...... re and adverse drug reactions.
@en
Highly active antiretroviral t ...... re and adverse drug reactions.
@nl
P2093
P1476
Highly active antiretroviral t ...... re and adverse drug reactions.
@en
P2093
P356
10.7326/0003-4819-131-2-199907200-00002
P407
P577
1999-07-01T00:00:00Z